Patent · US Active

Antitumor compound targeting IDH2 mutation and method of use thereof

US10155722B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignees

Inventors

Shulong Wang · Beijing, CN
Na Zhao · Beijing, CN
Xijie Liu · Beijing, CN
Yuandong Hu · Beijing, CN
Hui Zhang · Jinan, CN
Hong Luo · Clemson, US
Yong Peng · Beijing, CN
Dengming Xiao · Longmont, US
Yongxin Han · Kirkland, CA
Xiquan Zhang · 安丰镇, CN
Xin Tian · 安丰镇, CN

Key dates

Filing date	Jul 29, 2016
Grant date	Dec 18, 2018
Priority date	—
Expiry date	Jul 29, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D409/12
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.